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Mycetoma is a chronic, specific, gran-
ulomatous progressive, and destructive
inflammatory disease of mainly the foot
caused by either fungi (eumycetoma) or
bacteria (actinomycetoma) [1]. Mycetoma
is endemic in many tropical and subtrop-
ical regions, and it prevails in what is
known as the mycetoma belt, which
stretches in bands between the latitudes
of 15u South and 30u North of the
equator. With massive international travel,
it also has been occasionally reported from
different temperate regions [1]. The triad
of a painless subcutaneous mass, multiple
sinus formation, and purulent or sero-
purulent discharge that contains grains is
characteristic of mycetoma. It usually
spreads to involve the skin, deep struc-
tures, and bone-producing massive defor-
mities. Due to these deformities, myceto-
ma has a high morbidity rate, with a huge
impact on the patient, family, and the
community [1].
Since mycetoma has been highly ne-
glected, much is still not known regarding
the susceptibility, resistance, infection
route, disease progression, and response
to medical treatment of mycetoma. Based
on antibody measurements in earlier
studies, it was demonstrated that although
most people living in mycetoma-endemic
areas are exposed to the causative agent,
only a few developed mycetoma [2,3].
Therefore, the question arises of why some
people develop mycetoma and others not,
and when mycetoma is developed, why
some patients respond well to treatment
and others not. The answer to these
questions could lie in the different reac-
tions toward M. mycetomatis by the immune
system between individuals who develop
mycetoma and individuals who do not.
So far there has been limited data on
immune response toward mycetoma in-
fection. The only data available were
derived from animal models and actino-
mycetoma patients. From mouse models
it was evident that mycetoma only oc-
curred when M. mycetomatis was inoculated
with an adjuvant (either soil or Freunds
incomplete adjuvant), both predisposing to-
ward a Th2 response [4,5]. Remarkably, in
1974, Cavanagh demonstrated that
M. mycetomatis emulsified in the Th1-predis-
posing Freunds complete adjuvant (FCA)
could not induce mycetoma in L20 mice
[6,7]. Furthermore, when Peripheral Blood
Mononuclear Cells (PBMCs) from actinomy-
cetoma patients were stimulated with anti-
gens from Nocardia brasiliensis, a Th2-type
cytokine profile was detected [8]. This could
indicate that the causative agent probably
induces a Th2 response that facilitates further
growth and the development of a clinically
significant mycetoma lesion. In order to
determine if a Th2 cytokine profile is indeed
associated with mycetoma development and
a Th1 cytokine profile with protection against
mycetoma, this prospective, cross-sectional
study was conducted at the Mycetoma
Research Centre and the Institute of Endem-
ic Diseases, University of Khartoum, Khar-
toum, Sudan, after obtaining ethical clear-
ance from the Soba University Hospital
Ethical Committee to determine the profile
of four cytokines in both healthy endemic
controls and mycetoma patients. The study
included 27 patients with confirmed eumy-
cetoma due to Madurella mycetomatis treated
with 800 mg/d ketoconazole and 21 normal
individuals from eumycetoma-endemic areas
(Table 1). The present study was approved by
the Ethics Committee of Soba University
Hospital, Khartoum, Sudan. Written in-
formed consents were obtained from the
participants prior to their enrollment in
the study. For each study, individual
10 ml of venous blood were collected in
heparinized blood collection tubes.
From the collected blood, peripheral
mononuclear cells were isolated using
Ficoll-Hypaque gradient centrifugation
as described previously [9]. Stimulation
of cells was done using 50 ml of unchar-
acterized culture filtrate of M. mycetoma-
tis. The culture filtrate of M. mycetomatis
was prepared by culturing M. mycetomatis
for 3 wk at 37uC in RPMI-1640 medi-
um supplemented with morpholinopro-
panesulfonic acid (MOPS) and phenol
red and by filtrating this through a
0.45 micron pore size filter joined to a
20 ml syringe to purify any mycelia and
debris. The filtered culture filtrate was
stored at 220uC until used. To stimu-
late the isolated PBMCs, 16106 cells
were plated into a 24-well flat-bottomed
cell culture plate. Stimulation of PBMCs
was done using 50 ml of culture filtrate
of M. mycetomatis. For each patient and
healthy control, some wells were left
unstimulated to serve as control. The
culture plates were incubated at 37uC
with 5% CO2. After 72 h, the cells were
harvested by centrifugation at
1,200 rpm for 3 min, and the superna-
tants were then collected for cytokine
measurement by sandwich ELISAs us-
ing BD OptEIA ELISA Set B (Catalog
No. 550534).
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Table 1. Patient demographics.
Eumycetoma Patients Healthy Endemic Controls
Number (n) 27 21
Gender (male/female) 22/5 19/2
Mean age years (range) 23.5 (9–45) 33.9 (22–53)
Lesion site Foot NA
Lesion size (n) Large 18 NA
Medium 5 NA
Small 4 NA
Ketoconazole responding (yes/no) 11/8 NA
Causative agent M. mycetomatis NA
NA, not applicable.
doi:10.1371/journal.pntd.0002081.t001
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After stimulating the PBMCs of both
patients and healthy endemic controls
with the M. mycetomatis antigen prepara-
tion, it was noted that the PBMCs of the
patients reacted differently to this antigen
than the healthy controls. Statistically
significantly higher IL-10 concentrations
were detected in all the patients (mean
458.2 pg/ml) compared to the healthy
controls (mean 30.7 pg/ml) (Figure 1A,
Mann–Whitney, p=0.004, GraphPad
Prism 5.01). In contrast, the INF-c con-
centrations were significantly higher in the
control population (mean 792.8 pg/ml)
than in the patient group (mean 77.4 pg/
ml) (Figure 1B, Mann–Whitney,
p=0.007). Generally it was noted that
when PBMCs produced INF-c upon
stimulation with the antigen, no IL-10
was produced and vice versa. There were
no significant differences in TNFa or
TGF-b concentrations between patients
and control groups (Figure 1C and 1D,
Mann–Whitney, p.0.05). In order to
determine if mycetoma patients with
larger lesions had higher levels of IL-10
and lower levels of INF-c, the IL-10 and
INF-c levels were stratified according to
lesion size. Although in general higher
concentrations of Il-10 and lower levels of
INF-c were found in the massive lesions, it
appeared that this was not statistically
different from the smaller lesion sizes
(Kruskall–Wallis, p.0.05; GraphPad
Prism 5.01). There is only one other study
with which we could use to compare our
results [10]. Castro–Matteotti used three
different Nocardia brasiliensis extracts to
stimulate PBMCs from seven actinomyce-
toma patients, seven tuberculosis patients,
and seven healthy controls and measured
the INF-c response [10]. None of the
extracts was able to stimulate INF-c
production in humans [10]. This is in
contrast to our findings. When we stimu-
lated the healthy controls in our study with
a M. mycetomatis extract, the PBMCs of the
healthy controls produced INF-c. Clearly,
the PBMC response toward eumycetoma
antigens and actinomycetoma antigens
differs.
At the moment, eumycetoma is treated
with surgery and prolonged antifungal
therapy with ketoconazole. Ketoconazole
is known to suppress the production of
Th2-type cytokines IL-4 and IL-5; there-
fore, the working mechanism of this drug
in mycetoma might be 2-fold: inhibiting
fungal growth and reversing the immune
system toward a Th1 response [11,12].
Unfortunately not all patients respond well
to ketoconazole treatment. Many still
show recurrent infections, even if the
fungal species itself is susceptible toward
this drug [13]. Furthermore, it also
determined if patients responding to
ketoconazole had different cytokine pro-
files than patients not responding to this
drug. All patients were treated with
800 mg/d of ketoconazole for at least
6 mo. If a patient was responding to this
treatment, the size of the lesion decreased,
discharging sinuses closed, and there was a
noted pain relief. According to these
criteria, the patients were further divided
into two groups: patients who responded
to 800 mg/d ketoconazole (n=11) and
those who did not respond (n=8). PBMCs
of patients who responded to ketoconazole
therapy produced similar levels of IL-10,
INF-c, TNF-a, or TGF-b as patients who
did not respond to this therapy (Mann–
Whitney, p= ns for all cytokines).
In conclusion, this study showed that
mycetoma patients produce high concen-
trations of IL-10 that correlate with the
disease severity. IFN-c seems to be
associated with protection against myceto-
ma, and it may indicate past subclinical
infections. The four cytokine concentra-
tion levels were not affected by a medical
treatment response. An important limita-
tion of the present study is the small
number of patients included. Further
studies at the field level in endemic areas
and on controls from nonendemic areas
that study cytokine profile in serum and in
the histopathological lesion are recom-
mended for more in-depth understanding
of the immune responses of the mycetoma
patients.
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Figure 1. Cytokine concentrations of stimulated PBMCs of eumycetoma patients and healthy controls. (A) IL-10 concentrations (pg/ml)
measured after stimulating PBMCs from eumycetoma patients and healthy endemic controls with M. mycetomatis antigen. Statistically significantly
different concentrations were found between eumycetoma patients and healthy controls (p=0.004) as determined by the Mann–Whitney U test. (B)
IFN-c concentrations (pg/ml) measured after stimulating PBMCs from eumycetoma patients and healthy endemic controls with M. mycetomatis
antigen. Statistically significantly different concentrations were found between eumycetoma patients and healthy controls (p=0.007) as determined
by the Mann–Whitney U test. (C) TNF-a concentrations (pg/ml) measured after stimulating PBMCs from eumycetoma patients and healthy endemic
controls with M. mycetomatis antigen. No statistically significantly different concentrations were found between eumycetoma patients and healthy
controls (p= 0.85) as determined by the Mann–Whitney U test. (D) TGF-b concentrations (pg/ml) measured after stimulating PBMCs from
eumycetoma patients and healthy endemic controls with M. mycetomatis antigen. No statistically significantly different concentrations were found
between eumycetoma patients and healthy controls (p=0.89) as determined by the Mann–Whitney U test.
doi:10.1371/journal.pntd.0002081.g001
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